BIOGEN INC. - COMMON STOCK

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

22 10月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

09 10月 2024 06:30:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 10月 2024 09:05:33 条件 NetDania Notify

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

08 10月 2024 06:30:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 10月 2024 11:25:18 条件 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

03 10月 2024 08:45:05 条件 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

02 10月 2024 14:08:16 条件 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 9月 2024 15:06:38 条件 NetDania Notify

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

24 9月 2024 00:00:00 条件 Nasdaq GlobeNewswire

Biogen Board Appoints Two New Independent Directors

12 9月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

04 9月 2024 06:30:34 条件 Nasdaq GlobeNewswire

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024

30 7月 2024 16:15:17 条件 Nasdaq GlobeNewswire

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

30 7月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

26 7月 2024 06:20:38 条件 Nasdaq GlobeNewswire

Biogen Completes Acquisition of Human Immunology Biosciences

02 7月 2024 08:16:51 条件 Nasdaq GlobeNewswire

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

27 6月 2024 18:39:36 条件 Nasdaq GlobeNewswire

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

24 6月 2024 06:30:00 条件 Nasdaq GlobeNewswire

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

09 6月 2024 18:37:43 条件 Nasdaq GlobeNewswire

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

03 6月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

30 5月 2024 15:51:04 条件 Nasdaq GlobeNewswire